Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next
Author: marsuculix One star, 50 posts Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 657  
Subject: Exel’ Management presents, 11/14/2014 R Date: 11/15/2012 2:11 AM
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Recommendations: 5
Hi fellow Fools,
The PDUFA date for Cabo is only a span of 2 weeks away – let’s have our fingers crossed!

At the Exelixis, Inc. (EXEL) Lazard Capital Markets 9th Annual Healthcare Conference Call November 14, 2012 Frank L. Karbe (Executive Vice President and Chief Financial Officer) gave some information regarding the clinical development of cabozantinib which I will comment today in my next post on this board.
http://seekingalpha.com/article/1008091-exelixis-management-...

Pipeline
At the end of the presentation Karbe gave some insight into the terms of the co-operation with Roche/Genentech (GDC-0973 / XL518) – anwering some ot the questions I have raised in my previous post on this bard. Ouote:
<< We participate 50-50 on the first 200 million of actual U.S. sales then sort of declines to 30% profit share for actual sales about 400 million. Outside of the U.S., we are eligible to receive low double-digit royalties. And so overall I think the economic stake that we have here is quite attractive.
Beyond that we also have a co-promotion option, which allows us to potentially fill up to 25% of total sales force for GC-0973. This option must be exercised within 12 months of receiving notification of the first patient being dosed in the pivotal study. Now if you look at ClinicalTrials.gov, you will see that the pivotal study is up and running. >>
As you see Exelixis must fill up 25% of total sales force within one year from now – cost implication?

Broad pipeline:
Outside of cabo, Exelixis has a fairly broad pipeline of partnered assets - future gems?.
1) GDC-0973 / XL518
2) Two PI3K inhibitors XL147 and XL765, which are in collaboration with Sanofi
3) XL880 similar compound to Cabo (also VEGF and MET inhibitor), partnered with GSK.

Update on cabo’ clinical development plan will follow soon…

Fool on
marsuculix, who is still very optimistic and thinks that his investment will give him sweet fruits!
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next

Announcements

Pencils of Promise - Back to School Drive
"Pencils of Promise works with communities across the globe to build schools and create programs that provide education opportunities for children."
Managing Your Wealth
Our own TMFHockeypop from Rule Your Retirement fame on the TV show Managing Your Wealth.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Post of the Day:
Value Hounds

My Big Fat Greek Splat
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement